Clinical Trial Update: A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating belimumab for chronic immune thrombocytopenia was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura
• Immune Thrombocytopenia

Drugs mentioned

• Belimumab (belimumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Purpura, Thrombocytopaenic, Idiopathic | Phase 2 | Status: WITHDRAWN